Tmax, drop-outs (EMA) [Regulatives / Guidelines]

posted by pash413 – India, 2012-03-28 19:04 (4200 d 03:49 ago) – Posting: # 8345
Views: 4,831

Dear HS
Thanks for your quick reply
  1. Our formulation is IR formulation, but the reported Tmax is around 6-10 hours.
  2. Further we want to know the the reason/regulatory expectation behind the analysing the drop out/ withdrawal subjects. Will it be useful to establish any correlation between adverse events with the plasma concentration data and may be used to rule out formulation performance as the reason of adverse events? then what about it's applicability for subject who dropout due to personal reason? Please share your view, as USFDA does not require analysis of such dropout subjects.

Complete thread:

UA Flag
 Admin contact
22,761 posts in 4,775 threads, 1,628 registered users;
16 visitors (0 registered, 16 guests [including 4 identified bots]).
Forum time: 22:54 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz